24小时热门版块排行榜

返回列表

dndxhb

木虫 (正式写手)

杜甫很无奈

应助: 10 (幼儿园)
金币: 3102
红花: 6
帖子: 531
在线: 355.1小时
虫号: 1241938
注册: 2011-03-22
性别: GG
专业: 药物化学

[交流] 辉瑞公司停止开发丙型肝炎药物已有5人参与

辉瑞制药有限公司(Pfizer Inc., PFE, 简称：辉瑞公司)已停止丙型肝炎药物的试验开发，退出了行业内为引入新一代丙型肝炎治疗药而进行的激烈竞争。

该公司发言人Victoria Davis称，公司在进行战略评估后决定停止Filibuvir的开发。她表示，这一决定与安全问题无关。

该药在停止开发前处于中期临床试验阶段

回复此楼

» 猜你喜欢

己酮可可碱过氧化杂质限度已经有2人回复
计算化学与人工智能驱动的MOFs性能预测与筛选技术已经有0人回复
药物学论文润色/翻译怎么收费? 已经有288人回复
求助Isoeugenol质量标准已经有0人回复
Gliclazide 已经有0人回复
塞替派/噻替哌（Thiotepa）质量控制已经有16人回复
研三实验求指导已经有0人回复
有没有大佬可以帮忙查下Trijardy XR和Qternmet XR历年销售数据呀已经有0人回复
金属材料多尺度计算模拟技术与应用：微观机理到宏观性能的集成工作已经有0人回复
酰胺水解求助已经有11人回复
中药材标准目录大全llp2026（含各省市中药材和炮制规范）已经有0人回复

» 本主题相关价值贴推荐，对您同样有帮助:

【转载】美国FDA称默克新药能快速治愈丙型肝炎已经有9人回复

杜甫很无奈

1楼 2013-03-12 00:06:05

已阅回复此楼关注TA 给TA发消息送TA红花 TA的回帖

迷你生物学

至尊木虫 (小有名气)

应助: 2 (幼儿园)
金币: 14449.7
帖子: 110
在线: 67.6小时
虫号: 1069967
注册: 2010-08-05
性别: GG
专业: 药物分析

★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+1, 谢谢交流。 2013-03-13 08:39:37

Combination of filibuvir and peginterferon alfa-2a/ribavirin evaluated in HCV patients

--------------------------------------------------------------------------------

Filibuvir (PF-00868554; Pfizer) has previously been evaluated as monotherapy in patients with hepatitis C (HCV), and whether the activity seen in that study could be enhanced by combination with peginterferon alfa-2a and ribavirin has now been assessed in a randomized, placebo-controlled trial. Patients with genotype 1 HCV (N = 35) were treated with filibuvir 200, 300 or 500 mg b.i.d. or placebo plus peginterferon alfa-2a 180 mcg/week and ribavirin 1000/1200 mg/day for 4 weeks, with the peginterferon/ribavirin treatment continuing for a further 44 weeks. During the 4-week filibuvir treatment period, the combination therapy was well tolerated, with headache, fatigue, insomnia and nausea the most common adverse events. Adverse events did not appear to be related to filibuvir dose. One serious adverse event related to treatment, elevated creatinine, was seen in the filibuvir 300 mg group. Mean reductions in HCV RNA at day 28 were -2.10, -4.46, -4.67 and -3.62 log10 IU/mL for the placebo and filibuvir 200, 300 and 500 mg groups, respectively. In these groups, 0, 60, 75 and 63% of patients achieved undetectable HCV RNA by week 4 (Jacobson, I. et al. 44th Annu Meet Eur Assoc Study Liver (EASL) (April 22-26, Copenhagen) 2009, Abst).